RxDoctor Payments DataLook up a doctor →

Paul Myers, MD

Cardiovascular Disease · Nashville, TNNPI 1245325661

Payments from drug & device makers

$489,242in general payments, 2019–2025

Across 410 payments — averaging $1193.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$330K
  • Medtronic$103K
  • Abbott$17K
  • CSL Behring$12K
  • Boehringer Ingelheim International GmbH$12K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$10K
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$5,69498%
  • Education$972%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$489,242 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$135,423
Medicare patients
518
Services billed
1,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab645$585,313
EliquisApixaban461$380,729
EntrestoSacubitril/Valsartan195$191,477
Praluent PenAlirocumab121$145,178
XareltoRivaroxaban142$131,892
JardianceEmpagliflozin178$128,189
FarxigaDapagliflozin Propanediol136$89,852
MultaqDronedarone Hcl59$49,452
VascepaIcosapent Ethyl69$44,912
NexletolBempedoic Acid62$41,794
Repatha SyringeEvolocumab61$39,910
OzempicSemaglutide30$30,296
Repatha PushtronexEvolocumab15$19,027
Ranolazine ErRanolazine89$16,974
Icosapent Ethyl39$14,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$390$380,729461 claims
NovartisEntresto$777$191,477195 claims
Johnson & JohnsonXarelto$66$131,892142 claims
Boehringer IngelheimJardiance$513$128,189178 claims
AstraZenecaFarxiga$341$89,852136 claims
Sanofi-aventis U.S. LLCMultaq$234$49,45259 claims
Esperion Therapeutics, Inc.Nexletol$34$41,79462 claims
Novo NordiskOzempic$759$30,29630 claims
AmgenCorlanor$720$13,47119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →